Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TYMP | P19971 | 3/20 | 0.41 |
| ▸ | TK2 | O00142 | 4/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080414 | 0.82 | TYMP (0.32) | TYMPTK2 | |
| SCHEMBL16631675 | 0.78 | MAPK1 (0.48) | MAPK1HPGDALDH1A1NPSR1TYMP | |
| SCHEMBL16631677 | 0.74 | MAPK1 (0.44) | MAPK1HPGDALDH1A1NPSR1TYMP | |
| SCHEMBL18081935 | 0.73 | MAPK1 (0.43) | MAPK1HPGDALDH1A1NPSR1TYMP | |
| SCHEMBL16631660 | 0.70 | HPGD (0.52) | MAPK1HPGDTK2TK1 | |
| SCHEMBL2183944 | 0.70 | MAPK1 (0.61) | MAPK1HPGDALDH1A1NPSR1TYMP | |
| SCHEMBL16631662 | 0.69 | HPGD (0.56) | MAPK1HPGDTK2TK1 | |
| SCHEMBL15110503 | 0.69 | TK2 (0.60) | MAPK1HPGDTYMPTK2TK1 | |
| SCHEMBL1058809 | 0.69 | MAPK1 (0.59) | MAPK1HPGDALDH1A1NPSR1TYMP | |
| Ammonia Solution, Strong SCHEMBL4194711 | 0.69 | MAPK1 (0.59) | MAPK1HPGDALDH1A1NPSR1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | MAPK1 4185/4885HPGD 3931/4885ALDH1A1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.